LIDDS has decided to concentrate its activities on three project areas
Kurs
+3,45%
Likviditet
0,00 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-08-28 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-29 | N/A | Årsstämma |
| 2025-05-29 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-22 | 09:30 | Bokslutskommuniké 2024 |
| 2024-11-21 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-28 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-30 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-16 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
| 2024-05-15 | - | Årsstämma |
| 2024-02-27 | - | Extra Bolagsstämma 2024 |
| 2024-02-22 | - | Bokslutskommuniké 2023 |
| 2023-11-28 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-30 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-30 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
| 2023-05-29 | - | Årsstämma |
| 2023-05-29 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-13 | - | Bokslutskommuniké 2022 |
| 2023-01-09 | - | Extra Bolagsstämma 2022 |
| 2022-11-28 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-02 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
| 2022-06-01 | - | Årsstämma |
| 2022-05-24 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-23 | - | Bokslutskommuniké 2021 |
| 2021-11-22 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-18 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-18 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
| 2021-05-17 | - | Årsstämma |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-19 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-15 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
| 2020-05-14 | - | Årsstämma |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-11-28 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-29 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-17 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
| 2019-05-16 | - | Årsstämma |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-28 | - | Bokslutskommuniké 2018 |
| 2018-11-29 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-30 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-17 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
| 2018-05-16 | - | Årsstämma |
| 2018-05-16 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-11-09 | - | Kvartalsrapport 2017-Q3 |
| 2017-10-06 | - | Extra Bolagsstämma 2017 |
| 2017-08-31 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-12 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
| 2017-05-11 | - | Årsstämma |
| 2017-05-11 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-23 | - | Bokslutskommuniké 2016 |
| 2016-10-27 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-24 | - | Kvartalsrapport 2016-Q2 |
| 2016-06-09 | - | Extra Bolagsstämma 2016 |
| 2016-04-22 | - | Årsstämma |
| 2016-04-22 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-21 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
| 2016-02-10 | - | Bokslutskommuniké 2015 |
| 2015-10-29 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-13 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-22 | - | X-dag ordinarie utdelning LIDDS 0.00 SEK |
| 2015-04-21 | - | Årsstämma |
| 2015-04-21 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-20 | - | Bokslutskommuniké 2014 |
| 2014-11-11 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-21 | - | Kvartalsrapport 2014-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
GOTHENBURG, SWEDEN – The board of LIDDS AB (publ) has decided to concentrate operations on the project areas Nanodotax, Nanoimod and NOV 202.
As part of the new board's strategic review, a decision has been made to concentrate LIDDS operations in three project areas; Nanodotax, Nanoimod and NOV202 (NOV202 was acquired in connection with the acquisition of Noviga, in spring 2024).
Because of this, further investments to other projects, including Liproca, are therefore stopped.
LIDDS will attend BIO-Europe in Stockholm in November, where the company will seek contact with potential partners for its three priority project areas.
"This is a natural step, where we are now focusing and concentrating LIDDS activities on our three most promising and interesting project areas. We have very interesting data for all these project areas, which we hope will generate interest from potential partners at BIO-Europe in Stockholm in November", says Daniel Lifveredson, chairman of the board of LIDDS.
For additional information, please contact
Mats Wiking, CEO and CFO
Phone: +46 (0)70 620 04 00
E-mail: mats.wiking@liddspharma.com
Daniel Lifveredson, Chairman of the Board
Telefon: +46 (0) 70-916 21 01
Email: d.li@excore.com
LIDDS’ Certified Adviser is Redeye AB
LIDDS in brief:
LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market.